GeoVax Labs (GOVX) Competitors $0.68 +0.01 (+1.32%) As of 07/11/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GOVX vs. ESLA, BDRX, SNYR, MAAQ, RANI, MRNS, ALLK, INKT, ENLV, and NRSNShould you be buying GeoVax Labs stock or one of its competitors? The main competitors of GeoVax Labs include Estrella Immunopharma (ESLA), Biodexa Pharmaceuticals (BDRX), Synergy CHC (SNYR), Mana Capital Acquisition (MAAQ), Rani Therapeutics (RANI), Marinus Pharmaceuticals (MRNS), Allakos (ALLK), MiNK Therapeutics (INKT), Enlivex Therapeutics (ENLV), and NeuroSense Therapeutics (NRSN). These companies are all part of the "pharmaceutical products" industry. GeoVax Labs vs. Its Competitors Estrella Immunopharma Biodexa Pharmaceuticals Synergy CHC Mana Capital Acquisition Rani Therapeutics Marinus Pharmaceuticals Allakos MiNK Therapeutics Enlivex Therapeutics NeuroSense Therapeutics GeoVax Labs (NASDAQ:GOVX) and Estrella Immunopharma (NASDAQ:ESLA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, media sentiment, analyst recommendations, risk, profitability and earnings. Does the media refer more to GOVX or ESLA? In the previous week, GeoVax Labs had 6 more articles in the media than Estrella Immunopharma. MarketBeat recorded 7 mentions for GeoVax Labs and 1 mentions for Estrella Immunopharma. Estrella Immunopharma's average media sentiment score of 1.89 beat GeoVax Labs' score of 0.99 indicating that Estrella Immunopharma is being referred to more favorably in the news media. Company Overall Sentiment GeoVax Labs Positive Estrella Immunopharma Very Positive Do institutionals & insiders believe in GOVX or ESLA? 6.1% of GeoVax Labs shares are owned by institutional investors. Comparatively, 0.4% of Estrella Immunopharma shares are owned by institutional investors. 1.2% of GeoVax Labs shares are owned by insiders. Comparatively, 55.1% of Estrella Immunopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has higher earnings and valuation, GOVX or ESLA? Estrella Immunopharma has lower revenue, but higher earnings than GeoVax Labs. Estrella Immunopharma is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGeoVax Labs$3.95M2.73-$24.99M-$3.65-0.19Estrella ImmunopharmaN/AN/A-$7.31M-$0.26-3.38 Is GOVX or ESLA more profitable? Estrella Immunopharma has a net margin of 0.00% compared to GeoVax Labs' net margin of -438.20%. GeoVax Labs' return on equity of -511.96% beat Estrella Immunopharma's return on equity.Company Net Margins Return on Equity Return on Assets GeoVax Labs-438.20% -511.96% -286.58% Estrella Immunopharma N/A -1,132.38%-273.91% Which has more risk & volatility, GOVX or ESLA? GeoVax Labs has a beta of 3.36, indicating that its stock price is 236% more volatile than the S&P 500. Comparatively, Estrella Immunopharma has a beta of 0.36, indicating that its stock price is 64% less volatile than the S&P 500. Do analysts rate GOVX or ESLA? GeoVax Labs currently has a consensus target price of $11.10, indicating a potential upside of 1,542.74%. Estrella Immunopharma has a consensus target price of $16.00, indicating a potential upside of 1,718.39%. Given Estrella Immunopharma's higher possible upside, analysts plainly believe Estrella Immunopharma is more favorable than GeoVax Labs.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GeoVax Labs 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29Estrella Immunopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryGeoVax Labs beats Estrella Immunopharma on 9 of the 16 factors compared between the two stocks. Get GeoVax Labs News Delivered to You Automatically Sign up to receive the latest news and ratings for GOVX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GOVX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GOVX vs. The Competition Export to ExcelMetricGeoVax LabsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.62M$2.97B$5.62B$9.10BDividend YieldN/A2.39%5.24%4.00%P/E Ratio-0.1920.7128.1320.27Price / Sales2.73288.39428.6398.72Price / CashN/A42.8637.4658.16Price / Book1.417.638.045.49Net Income-$24.99M-$55.05M$3.18B$250.45M7 Day Performance40.74%8.43%3.62%4.78%1 Month Performance-40.73%5.42%4.05%7.67%1 Year Performance-75.69%2.03%30.00%16.43% GeoVax Labs Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GOVXGeoVax Labs2.3014 of 5 stars$0.68+1.3%$11.10+1,542.7%-76.7%$10.62M$3.95M-0.1910Analyst RevisionESLAEstrella Immunopharma3.1895 of 5 stars$0.88flat$16.00+1,718.2%-35.3%$31.83MN/A-3.38N/ABDRXBiodexa Pharmaceuticals0.3148 of 5 stars$0.87+0.8%N/AN/A$31.63MN/A0.0020Positive NewsSNYRSynergy CHC3.9783 of 5 stars$3.37+4.0%$10.00+196.7%N/A$30.97M$34.83M0.0040Gap UpMAAQMana Capital AcquisitionN/A$3.80+3.3%N/A+589.0%$30.88MN/A0.001RANIRani Therapeutics1.8676 of 5 stars$0.54+0.2%$7.33+1,267.4%-82.1%$30.83M$1.03M-0.54110MRNSMarinus Pharmaceuticals2.2262 of 5 stars$0.55-0.2%$3.92+613.3%-58.7%$30.32M$30.99M-0.22110ALLKAllakos2.9503 of 5 stars$0.33flat$2.00+507.7%N/A$29.74MN/A-0.16190INKTMiNK Therapeutics1.2414 of 5 stars$7.28+0.6%$37.50+415.5%+562.4%$29.03MN/A-2.8930Trending NewsGap UpENLVEnlivex Therapeutics2.872 of 5 stars$1.21+2.5%$10.00+726.4%-8.6%$28.62MN/A-1.8370Positive NewsNRSNNeuroSense Therapeutics2.665 of 5 stars$2.09+9.4%$14.00+569.9%+101.0%$28.57MN/A-3.8710News CoverageAnalyst ForecastHigh Trading Volume Related Companies and Tools Related Companies ESLA Competitors BDRX Competitors SNYR Competitors MAAQ Competitors RANI Competitors MRNS Competitors ALLK Competitors INKT Competitors ENLV Competitors NRSN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GOVX) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GeoVax Labs Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GeoVax Labs With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GOVX Stock Alerts